Table 2.
Baseline Characteristics by Treatment Group
| Baseline Characteristics | Treatment As Usual (n = 29) | Pharm-CAT (n = 32) | CAT (n = 34) |
| % Male | 62.07 | 43.75 | 64.71 |
| % Hispanic | 27.59 | 38.71 | 29.41 |
| % Non-Hispanic White | 44.83 | 38.71 | 29.41 |
| Age, y | 39 (SD = 22.1) | 40 (SD = 11.1) | 37 (SD = 9.4) |
| Education | 11.7 (SD = 2.3) | 11.3 (SD = 2.6) | 12.1 (SD = 2.3) |
| BPRS psychosis factor | 2.7 (SD = 2.34) | 2.6 (SD = 1.47) | 2.5(SD = 1.34) |
| Social and occupational functioning scale | 45.6 (SD = 8.07) | 45.5 (SD = 8.90) | 45.9 (SD = 8.19) |
| Baseline medication | |||
| % Risperidone | 41.4 | 21.9 | 38.2 |
| % Olanzapine | 34.5 | 46.9 | 41.2 |
| % Other | 24.1 | 31.2 | 20.6 |
Note: No significant group differences (all P′s with one exception >.40; trend for fewer males in Pharm-CAT [CAT focused only on medication and appointment adherence] P < .08). CAT, cognitive adaptation training; BPRS, Brief Psychiatric Rating Scale.